Evaxion A (EVAX) Operating Income (2020 - 2025)
Evaxion A's (EVAX) quarterly Operating Income came in at -$4.3 million in Q2 2025, up 5.26% YoY from -$4.1 million in Q2 2024, and down 12.2% on a QoQ basis from -$3.9 million in Q1 2025.
Evaxion A (EVAX) Operating Income (2020 - 2025) Analysis & Trends
Evaxion A (EVAX) has 6 years of Operating Income data on file, last reported at -$4.3 million in Q2 2025.
- Quarterly Operating Income rose 5.26% year-over-year to -$4.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$14.0 million (up 26.91% YoY) and the FY2025 annual result came in at -$9.2 million, up 37.32% from the prior year.
- Operating Income fell to -$4.3 million in Q2 2025, from -$3.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$1.7 million in Q3 2024 to a low of -$18.1 million in Q3 2021.
- A 5-year average of -$6.3 million and a median of -$5.7 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income sank 68.69% — and 2024, when it surged 69.96%.
- Tracing EVAX's Operating Income over 5 years: stood at -$7.7 million in 2021, then advanced by 15.49% to -$6.5 million in 2022, then soared by 33.12% to -$4.4 million in 2023, then climbed by 7.79% to -$4.0 million in 2024, then declined by 7.85% to -$4.3 million in 2025.
- The last three Operating Income figures came in at -$4.3 million (Q2 2025), -$3.9 million (Q1 2025), and -$4.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 133.12 Mn |
| 10 | Evaxion A | 27.54 Mn | 27.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.34 Mn |
| Mar 31, 2025 | -3.87 Mn |
| Dec 31, 2024 | -4.02 Mn |
| Sep 30, 2024 | -1.73 Mn |
| Jun 30, 2024 | -4.58 Mn |
| Mar 31, 2024 | -4.40 Mn |
| Dec 31, 2023 | -4.36 Mn |
| Sep 30, 2023 | -5.76 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -6.53 Mn |
| Dec 31, 2022 | -6.53 Mn |
| Sep 30, 2022 | -6.08 Mn |
| Jun 30, 2022 | -6.26 Mn |
| Mar 31, 2022 | -6.40 Mn |
| Dec 31, 2021 | -7.72 Mn |
| Sep 30, 2021 | -18.11 Mn |
| Jun 30, 2021 | -12.20 Mn |
| Mar 31, 2021 | -5.18 Mn |
| Dec 31, 2020 | -4.65 Mn |
| Sep 30, 2020 | -11.92 Mn |